Ir para o conteúdo principal
Grafa
Health
Evogene Q2 net loss narrows to $1.8 million
Image for illustrative purposes only. Not a real photo.

Evogene Q2 net loss narrows to $1.8 million

Share
  • Evogene reported a Q2 2026 net loss of about $1.8 million, narrowing from $4.7 million a year earlier as operating costs and discontinued-operation losses declined.
  • First-half revenue fell to about $0.7 million from $2.9 million, while Evogene ended June with approximately $9.3 million in cash.
  • The company is concentrating on AI-driven computational chemistry, with six active drug collaborations and ChemPass AI covering about 110 billion molecules.

Evogene (NASDAQ:EVGN) reported a Q2 2026 net loss of approximately $1.8 million, narrowing from about $4.7 million in the prior-year quarter.

Q2 revenue declined to roughly $0.3 million from $0.5 million, mainly following the May conclusion of AgPlenus' agreement with Bayer.

Evogene cut its workforce from 117 employees in December 2024 to 38 in August 2026 and expects 2026 cash usage of approximately $8.5–$9.5 million.

First-half revenue fell to approximately $0.7 million from $2.9 million, while cash totaled $9.3 million and Q2 cash usage was about $2.1 million.

Evogene said it has six active drug collaborations and expanded ChemPass AI's virtual chemical space to approximately 110 billion molecules while focusing resources on pharmaceutical and crop-protection programs.

Perguntas frequentes